Immunotherapy combo shows promise against early lung cancer in small trial
NCT ID NCT05775796
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tested the drug serplulimab (an immunotherapy) combined with standard chemotherapy in 30 people with stage II-IIIA non-small cell lung cancer that could be surgically removed. The treatment was given before and after surgery to see if it could shrink tumors and improve outcomes. The study is complete, and results will help determine if this combination is safe and effective enough for larger trials.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Serplulimab combined with chemotherapy (paclitaxel or pemetrexed plus cisplatin or carboplatin)
What this could lead to
If successful, this could point toward a more effective treatment approach for early-stage lung cancer, potentially improving surgical outcomes and reducing recurrence.
What could go wrong
This is a small, early-phase trial with only 30 participants and no comparison group, so results may not be conclusive. The combination therapy also carries risks of side effects from both immunotherapy and chemotherapy.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL-CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Fudan University Shanghai Cancer Center
Shanghai, Shanghai Municipality, 200032, China